CSIMarket
 


Pharmacyte Biotech Inc   (PMCB)
Other Ticker:  
 

Pharmacyte Biotech Inc 's Quick Ratio

PMCB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 14.01 below Pharmacyte Biotech Inc average.

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Quick Ratio than Pharmacyte Biotech Inc in second quarter 2023. While Quick Ratio total ranking has improved so far during the II Quarter 2023 to 205, from total ranking in the first quarter 2023 at 223.

Explain Quick Ratio?
How much Cash & cash equivalents PMCB´s has?
What are PMCB´s Current Liabilities?


PMCB Quick Ratio (Oct 31 2023)
II. Quarter
(Jul 31 2023)
I. Quarter
(Apr 30 2023)
IV. Quarter
(Jan 31 2023)
III. Quarter
(Oct 31 2022)
II. Quarter
Y / Y Current Liabilities Change 299.62 % 39.34 % -16.72 % 35.05 % 604.45 %
Y / Y Cash & cash equivalent Change -4.6 % -9.2 % -20.33 % -16.16 % -11.47 %
Quick Ratio MRQ 14.01 49.18 115.99 87.75 58.7
PMCB's Total Ranking # 205 # 223 # 58 # 33 # 46
Seq. Current Liabilities Change 245.16 % 158.78 % -29.14 % -36.86 % 20.35 %
Seq. Cash & cash equivalent Change -1.66 % 9.73 % -6.33 % -5.62 % -6.4 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 33
Overall Market # 106


Quick Ratio Statistics
High Average Low
467.11 30.16 0.01
(Oct 31 2021)   (Oct 31 2012)




Financial Statements
Pharmacyte Biotech Inc 's Current Liabilities $ 5 Millions Visit PMCB's Balance sheet
Pharmacyte Biotech Inc 's Cash & cash equivalent $ 73 Millions Visit PMCB's Balance sheet
Source of PMCB's Sales Visit PMCB's Sales by Geography


Cumulative Pharmacyte Biotech Inc 's Quick Ratio

PMCB's Quick Ratio for the trailling 12 Months

PMCB Quick Ratio

(Oct 31 2023)
II. Quarter
(Jul 31 2023)
I. Quarter
(Apr 30 2023)
IV. Quarter
(Jan 31 2023)
III. Quarter
(Oct 31 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth 299.62 % 39.34 % -16.72 % 35.05 % 604.45 %
Y / Y Cash & cash equivalent TTM Growth -4.6 % -9.2 % -20.33 % -16.16 % -11.47 %
Quick Ratio TTM 35.34 68.88 78.6 80.66 89.09
Total Ranking TTM # 2258 # 1828 # 1689 # 2111 # 9
Seq. Current Liabilities TTM Growth 245.16 % 158.78 % -29.14 % -36.86 % 20.35 %
Seq. Cash & cash equivalent TTM Growth -1.66 % 9.73 % -6.33 % -5.62 % -6.4 %


On the trailing twelve months basis Due to in Current Liabilities in the II Quarter 2023 to $5.24 millions, cumulative Quick Ratio decreased to 35.34 above the PMCB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 151 other companies have achieved higher Quick Ratio than Pharmacyte Biotech Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 1828 to 2258.

Explain Quick Ratio?
How much Cash & cash equivalents PMCB´s has?
What are PMCB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 152
Healthcare Sector # 842
Within the Market # 2258


trailing twelve months Quick Ratio Statistics
High Average Low
131.6 30.43 0.32
(Jul 31 2022)   (Jan 31 2020)




Companies with similar Quick Ratio in the quarter ending Oct 31 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioOct 31 2023 MRQ Cash & cash equivalentOct 31 2023 MRQ Current Liabilities
Acumen Pharmaceuticals Inc   35.33 $ 215.434  Millions$ 6.098  Millions
Vaxcyte Inc   33.62 $ 1,265.684  Millions$ 37.650  Millions
Creative Medical Technology Holdings Inc   29.42 $ 11.974  Millions$ 0.407  Millions
Revolution Medicines Inc   27.45 $ 813.195  Millions$ 29.627  Millions
Cortexyme Inc   27.34 $ 61.593  Millions$ 2.253  Millions
Apogee Therapeutics inc   24.62 $ 422.854  Millions$ 17.178  Millions
Intensity Therapeutics Inc   21.61 $ 15.649  Millions$ 0.724  Millions
Cullinan Oncology Inc   21.30 $ 466.430  Millions$ 21.897  Millions
Krystal Biotech Inc   20.38 $ 562.069  Millions$ 27.583  Millions
Prokidney Corp  19.51 $ 396.334  Millions$ 20.311  Millions
Graphite Bio Inc   18.66 $ 233.986  Millions$ 12.537  Millions
Tourmaline Bio Inc   18.14 $ 147.024  Millions$ 8.105  Millions
Compass Therapeutics Inc   17.94 $ 163.703  Millions$ 9.124  Millions
Avrobio Inc   17.90 $ 105.842  Millions$ 5.912  Millions
4d Molecular Therapeutics Inc   17.60 $ 319.664  Millions$ 18.163  Millions
Icosavax Inc   17.59 $ 229.206  Millions$ 13.030  Millions
Neumora Therapeutics Inc   17.50 $ 509.565  Millions$ 29.123  Millions
Hillevax Inc   17.11 $ 324.410  Millions$ 18.958  Millions
Fusion Pharmaceuticals Inc   16.92 $ 191.348  Millions$ 11.312  Millions
Crispr Therapeutics Ag  15.64 $ 1,739.826  Millions$ 111.234  Millions
Denali Therapeutics Inc   15.58 $ 1,109.256  Millions$ 71.180  Millions
Cabaletta Bio Inc   15.49 $ 164.391  Millions$ 10.616  Millions
Voyager Therapeutics Inc   14.51 $ 252.936  Millions$ 17.427  Millions
Pharmacyte Biotech Inc   14.01 $ 73.425  Millions$ 5.240  Millions
Iteos Therapeutics Inc   13.82 $ 599.027  Millions$ 43.349  Millions
Caribou Biosciences Inc   13.78 $ 338.488  Millions$ 24.572  Millions
Vor Biopharma Inc   13.75 $ 160.098  Millions$ 11.645  Millions
Aura Biosciences Inc   13.68 $ 149.076  Millions$ 10.894  Millions
Vigil Neuroscience Inc   13.18 $ 133.643  Millions$ 10.142  Millions
Anavex Life Sciences Corp   13.00 $ 151.024  Millions$ 11.617  Millions

Date modified: 2023-12-19T19:04:17+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com